Highlights
- A renamed medicines manufacturer has expanded its German cannabis supply arrangement into a larger exclusive deal.
- Minimum acquisition commitments offer revenue visibility, though pricing and volumes were not spelled out.
- A non-binding depression therapy proposal hints at ambitions beyond cannabis.
The parent of Breathe Life Sciences
has made Germany central to its cannabis story, expanding a supply agreement with ADREXpharma earlier this year before changing its name from Bioxyne in June. Germany does reshape the picture for this Australian medicines manufacturer, but the agreement's value depends on deliveries that have yet to be shown in the material available. As Britain BLS Pharmaceuticals continues operating within the All Ordinaries, growing attention is also being directed towards ASX Cannabis Stocks as companies across the sector navigate changing market conditions.
Britain BLS Pharmaceuticals is among the All Ords names drawing attention in ASX today coverage.
A new name on the screen
The company now trades under a new name, with Capital.com recording the change from Bioxyne in June. Its fact sheet describes a Sydney-based group making and distributing ca...